Le Lézard
Classified in: Ebola virus, Health
Subject: SVY

Global Bi-Specific Antibodies (BLINCYTO, Hemlibra & Removab) Market 2018-2022



DUBLIN, Sept. 5, 2018 /PRNewswire/ --

Research and Markets Logo. (PRNewsFoto/Research and Markets) (PRNewsfoto/Research and Markets)

The "Global Bi-Specific Antibodies Market Forecast to 2022" report has been added to ResearchAndMarkets.com's offering.

Global Bi-Specific Antibodies Market Forecast to 2022, the Global Bi-Specific Antibodies Market is anticipated to witness a double digit growth during the forecast period.

The report provides information about the current and future scenario of this market. The report also highlights the major drivers, such as increasing incidences of diseases and increasing demand for effective treatment, for the Global Bi-Specific Antibodies Market. Furthermore, the report also gives information related to the commercially available bi-specific antibody drugs.

Moreover, few hindrances, such as production hurdles and regulatory challenges, which are slowing down the growth of the Global Bi-Specific Antibodies Market, have also been mentioned in the report. In addition, the report also highlights various trends and developments taking place in this market.

Furthermore, in this report, we have structured the information regarding bi-specific antibodies at various stages of clinical development. The pipeline chapter provides in depth analysis of bi-specific antibodies by clinical phase, indications for which they are being developed, and technology. Additionally, the study provides all-inclusive current analysis of various bi-specific antibodies in advanced as well as early stages of development. Moreover, our report places emphasis on the strategic collaborations that can impact industry's growth.

The prominent players in Global Bi-Specific Antibodies Market have been discussed in the last section of the report. A brief business overview and financial information about each of these players has been provided, along with their product portfolios, product pipeline and recent developments. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the Global Bi-Specific Antibodies Market.

Key Topics Covered:

1. Analyst View

2. Research Methodology

3. Bi-Specific Antibodies - An Introduction

4. Global Bi-Specific Antibodies Market Outlook to 2022
4.1 BLINCYTO
4.2 Hemlibra
4.3 Removab

5. Bi-Specific Antibodies Pipeline Analysis
5.1 By Clinical Phase
5.2 By Indication
5.3 By Technology

6. Market Dynamics
6.1 Drivers
6.1.1 Rising Global Cancer Epidemics
6.1.2 Bi-Specific Antibodies Improving the Targeting Capabilities of Traditional mAbs
6.1.3 T-cells in Bi-Specific Antibodies Mediated Immunotherapy
6.1.4 Increasing Demand for Bi-Specific/Double Barreled Antibodies
6.2 Challenges
6.2.1 Production Hurdles in Bi-Specific Antibodies Development
6.2.2 Regulatory Challenges

7. Current Status of Major Bi-Specific Antibodies in Pipeline
7.1 BLINCYTO/Blinatumomab - Amgen Inc.
7.2 ABT-122 - AbbVie Inc.
7.3 MCLA-128 - Merus N.V.
7.4 ALX-0761/M1095 - Ablynx
7.5 MGD006/S80880 - MacroGenics, Inc.
7.6 ZW25 - Zymeworks Inc.

8. Trends and Developments
8.1 Bi-specific Antibody Application for Tumor Therapy
8.2 Bi-specific Antibodies Development Against Myeloma
8.3 Bi-specific Antibody Agreement with EpimAb Biotherapeutics
8.4 B-specific Antibody Development against Multiple Ebola viruses

9. Strategic Collaborations in the Bi-Specific Antibodies Industry

10. Competitive Assessment
10.1 Amgen Inc.
10.2 F. Hoffman La Roche Ltd.
10.3 AbbVie Inc.
10.4 OncoMed Pharmaceuticals, Inc.
10.5 Glenmark Pharmaceuticals Limited
10.6 Xencor, Inc.
10.7 MacroGenics, Inc.
10.8 Aptevo Therapeutics Inc.
10.9 Ligand Pharmaceuticals, Inc.
10.10 Regeneron Pharmaceuticals, Inc.
10.11 Fresenius SE & Co. KGaA
10.12 Merus N.V.

For more information about this report visit https://www.researchandmarkets.com/research/n98jcv/global?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

16 nov 2018
Johnson Fistel, LLP announced that a class action has been commenced on behalf of purchasers of Trevena, Inc. common stock during the period between May 2, 2016 and October 9, 2018 (the "Class Period"). If you wish to serve as lead plaintiff, you...

16 nov 2018
LAKE ORION, Mich., Nov. 16, 2018 /PRNewswire-PRWeb/ -- Most of the time, vaginal discharge is perfectly normal and an essential function in the female reproductive system. However, changes in the color, smell, or consistency could be signs of an...

16 nov 2018
ROCHESTER, Mich., Nov. 16, 2018 /PRNewswire-PRWeb/ -- Women's Excellence in Rochester, Michigan, will now offer treatment options to patients suffering from chronic pelvic pain. In addition to oncology services, the new center will specialize in the...

16 nov 2018
As American Diabetes Month kicks off this November to raise awareness for the disease that impacts more than 30 million Americans, MobileHelp® Healthcare, a leader in personal and enterprise healthcare technology solutions, announced expanded...

16 nov 2018
PITTSBURGH, Nov. 16, 2018 /PRNewswire-PRWeb/ -- MedVet is pleased to announce its expansion into Pittsburgh, Pennsylvania with the addition of University Veterinary Specialists (UVS), now known as MedVet Pittsburgh. The City Vets and VetNow divisions...

16 nov 2018
PHOENIX, Nov. 16, 2018 /PRNewswire-PRWeb/ -- America's families are buckling under the financial burden of caring for their children and their aging parents at the same time. Most turn a blind eye to the Silver Tsunami desperately hoping it won't hit...




News published on 5 september 2018 at 17:00 and distributed by: